Nicholas Hollmeyer Lynton Sells 6,464 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX) insider Nicholas Hollmeyer Lynton sold 6,464 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total value of $23,722.88. Following the completion of the sale, the insider now owns 91,771 shares of the company’s stock, valued at approximately $336,799.57. The trade was a 6.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cardlytics Price Performance

Cardlytics stock opened at $3.44 on Wednesday. The company’s 50 day simple moving average is $3.90 and its 200-day simple moving average is $4.78. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. Cardlytics, Inc. has a 1 year low of $2.89 and a 1 year high of $20.52. The company has a market capitalization of $174.83 million, a price-to-earnings ratio of -0.56 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company had revenue of $67.06 million for the quarter, compared to analyst estimates of $57.77 million. During the same quarter in the previous year, the company earned ($0.26) earnings per share. The firm’s quarterly revenue was down 15.1% compared to the same quarter last year. As a group, equities research analysts expect that Cardlytics, Inc. will post -1.52 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CDLX shares. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Evercore ISI started coverage on shares of Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.92.

Hedge Funds Weigh In On Cardlytics

A number of hedge funds and other institutional investors have recently bought and sold shares of CDLX. Geode Capital Management LLC increased its stake in Cardlytics by 7.5% during the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock worth $3,371,000 after purchasing an additional 73,484 shares during the period. Marshall Wace LLP grew its holdings in shares of Cardlytics by 6.8% in the second quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock valued at $6,685,000 after purchasing an additional 52,081 shares in the last quarter. RBF Capital LLC increased its stake in Cardlytics by 311.9% during the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock worth $1,562,000 after buying an additional 369,620 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Cardlytics by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock worth $1,249,000 after buying an additional 11,388 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its position in Cardlytics by 1,273.2% in the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after buying an additional 354,474 shares during the period. 68.10% of the stock is currently owned by hedge funds and other institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.